Treatment of Disseminated High Grade Lymphoma

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Interest of the use of pegylated liposomal doxorubicin (caélyx)

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French Innovative Leukemia Organisation
• Treatments: Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• high grade lymphoma

• disseminated

• > 60 years old and < 75

• informed consent signed

• cardiac state compatible with antracyclin

• ECOG Exclusion Criteria:

• patients > 75 years old

• Cardiac insufficiency